Drugging IGF-1R in cancer: New insights and emerging opportunities

Panpan Wang; Victor CY. Mak; Lydia WT. Cheung

doi:10.1016/j.gendis.2022.03.002

您当前的位置：

首页 >

文章列表页 >

Drugging IGF-1R in cancer: New insights and emerging opportunities

Review article | 更新时间：2023-08-29

- Drugging IGF-1R in cancer: New insights and emerging opportunities
- Drugging IGF-1R in cancer: New insights and emerging opportunities
- Genes & Diseases 2023年10卷第1期
- 作者机构：
  
  School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong,Hong Kong SAR,China
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.03.002
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-1-1，
扫描看全文
Drugging IGF-1R in cancer: New insights and emerging opportunities[J]. Genes & Diseases, 2023,10(1).

Panpan Wang, Victor CY. Mak, Lydia WT. Cheung. Drugging IGF-1R in cancer: New insights and emerging opportunities[J]. Genes & Diseases, 2023,10(1).
Drugging IGF-1R in cancer: New insights and emerging opportunities[J]. Genes & Diseases, 2023,10(1). DOI： 10.1016/j.gendis.2022.03.002.

Panpan Wang, Victor CY. Mak, Lydia WT. Cheung. Drugging IGF-1R in cancer: New insights and emerging opportunities[J]. Genes & Diseases, 2023,10(1). DOI： 10.1016/j.gendis.2022.03.002.

摘要

Abstract

The insulin-like growth factor (IGF) axis plays important roles in cancer development and metastasis. The type 1 IGF receptor (IGF-1R) is a key member in the IGF axis and has long been recognized for its oncogenic role in multiple cancer lineages. Here we review the occurrence of IGF-1R aberrations and activation mechanisms in cancers

which justify the development of anti-IGF-1R therapies. We describe the therapeutic agents available for IGF-1R inhibition

with focuses on the recent or ongoing pre-clinical and clinical studies. These include antisense oligonucleotide

tyrosine kinase inhibitors and monoclonal antibodies which may be conjugated with cytotoxic drug. Remarkably

simultaneous targeting of IGF-1R and several other oncogenic vulnerabilities has shown early promise

highlighting the potential benefits of combination therapy. Further

we discuss the challenges in targeting IGF-1R so far and new concepts to improve therapeutic efficacy such as blockage of the nuclear translocation of IGF-1R.

关键词

Keywords

CancerIGF-1RTargeted therapyMetastasisCombination therapy

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities

The emerging role of Arid5a in cancer: A new target for tumors

MicroRNA-9 as a paradoxical but critical regulator of cancer metastasis: Implications in personalized medicine

The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer